Docket No.: 20269/1201776-US2

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jav D. Kranzler et al.

Application No.: 10/623,431

Filed: July 18, 2003

Confirmation No.: 4067

Art Unit: 1614

Examiner: R. Cook

METHODS OF TREATING For:

> FIBROMYALGIA SYNDROME, CHRONIC FATIGUE SYNDROME AND PAIN

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment Commissioner for Patents P O Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark

Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Our check in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: November 16, 2005

Respectfully submitted.

Paul M. Zagar Paul M. Zagar Registration No.: 52,392

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257 (212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant



PTC/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/AB/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/623,431-Conf. #4067	
				Filing Date	July 18, 2003	
				First Named Inventor	Jay D. Kranzler	
				Art Unit	1614	
				Examiner Name	R. Cook	
Sheet	1	of	1	Attorney Docket Number	20269/1201776-US2	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	τ°

\*\*EXAMINES. Intel I returns constants, whether or not classes is necessarily and the property of the property

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2			
/AH/	CA	Reimann, et al., Effects of the Central Analgesic Tramadol on the Uptake and Release of Noradrenaline and dopamine in vitro, Br J Pharmacol. 1993, Mar; 108(3):806-11				
/AH	СВ	Reimann et al., Interaction of the Central Analgesic, Tramadol, with the Uptake and Release of 5-hydroxytryptamine in the rat brain in vitro, Br J Pharmacol. 1992 Jan; 105(1):147-51				
/AH/	СС	Hara, et al., The Effects of Tramadol and Its Metabolite on Glycine, -Aminobutyric AcidA, and N-Methyl-D-Aspartate Receptors Expressed in Xenopus Oocytes				
/AH	CD	Bymaster et al., Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

{W:\202 69\1201	/Alicia Hughes/	Date Considered	08/14/2010